Ms. Schaeffler joined Zymeworks in January 2024, bringing over 27 years of experience in the biotechnology and biopharma industries. Prior to joining Zymeworks, Ms. Schaeffler was Vice President of Clinical Operations at Syndax Pharmaceuticals, a clinical-stage oncology company developing first-in-class therapies for acute leukemias and chronic graft-versus host disease. Ms. Schaeffler has held senior roles covering clinical development and operations, leading departments and project development teams through all phases of clinical trials, culminating in regulatory filings and drug approvals. She has worked for organisations including Lundbeck, Alder Biopharmaceuticals (acquired by Lundeck), Poniard Pharmaceuticals (formerly NeoRx, Corporation), Pathogenesis and Chiron (acquired by Novartis) and PATH. Ms. Schaeffler holds an MBA and a bachelor’s degree in Bacteriology from the University of California.